Caring Cross Unveils Affordable Genetic Therapy Strategies
New press release announces the role of Caring Cross, a non-profit organization, in a newly published white paper from the Innovative Genomics Institute, titled “Making Genetic Therapies Affordable and Accessible.” The white paper is the result of yearlong research and focuses on strategies to increase the affordability and accessibility of genetic therapies, including CAR-T technology […]
Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
HOUSTON, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) — Invectys, Inc. and CTMC, a joint venture between MD Anderson Cancer Center and National Resilience, Inc., today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 1/2a clinical study of IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLA-G) targeting chimeric antigen […]
The future of ALL treatment: moving away from stem cell transplantation
Nicholas Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into future treatment approaches in acute lymphoblastic leukemia (ALL), highlighting the growing role of inotuzumab ozogamicin, blinatumomab, and CAR-T cells. Dr Short further explains the importance of moving away from stem cell transplantation and bringing novel agents and CAR-T therapy […]
CAR T-Cell Therapy: Ask Dr. Alaa Ali
Alaa Ali, MD, MSC, is a clinician, instructor, and investigator in clinical and translational research at MedStar Georgetown’s Stem Cell Transplant and Cellular Immunotherapy program. In the following video, Dr. Alaa Ali explains what CAR T-cell therapy is and how it works, what the process is for creating CAR T-cells to fight cancer, the success […]